Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD L SCHWARTZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1780793331
CMS profile
307599
Location
HATTIESBURG, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$129,717.37

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $127,472.51 152
E.R. Squibb & Sons, L.L.C. $596.84 3
GE HEALTHCARE $500.00 1
ABBVIE INC. $268.63 12
Eisai Inc. $247.75 9
Octapharma USA, Inc. $122.72 6
ACADIA Pharmaceuticals Inc $117.11 5
Biogen, Inc. $115.33 1
Novartis Pharmaceuticals Corporation $76.75 3
GENZYME CORPORATION $30.95 1
Alexion Pharmaceuticals, Inc. $30.31 1
PFIZER INC. $29.15 2
UCB, Inc. $23.44 1
Axsome Therapeutics, Inc. $22.10 1
Lundbeck LLC $17.09 1
Boston Scientific Corporation $16.39 1
Amgen Inc. $15.33 1
Janssen Biotech, Inc. $14.97 1

Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD L SCHWARTZ

NPI 1780793331 · CMS profile ID 307599

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

HATTIESBURG, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RONALD L SCHWARTZ, NPI 1780793331, CMS profile ID 307599, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780793331?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $129,717.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–202 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $108.2201/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186935462 CMS
Lilly USA, LLC $828.6501/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186935464 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,362.08 19
PY2020 $1,585.74 11
PY2021 $23,400.62 33
PY2022 $65,404.61 137
PY2023 $15,886.54 67
PY2024 $114,744.56 166
PY2025 $129,717.37 202

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,004.87 1
PY2025 Principal investigator $250,861.10 38
PY2024 Recipient $2,603.10 1
PY2024 Principal investigator $598,132.36 36
PY2023 Principal investigator $1,027,486.78 32
PY2022 Principal investigator $652,797.27 31
PY2021 Principal investigator $743,347.47 27
PY2020 Principal investigator $718,371.30 49
PY2019 Recipient $124.18 1
PY2019 Principal investigator $1,218,778.20 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $14,976.00 12/29/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175398665
Principal investigator 1 Janssen Research & Development, LLC $871.00 12/22/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398721
Principal investigator 1 Eisai Inc. $3,008.70 12/15/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559028
Principal investigator 1 Janssen Research & Development, LLC $23,467.00 12/15/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175398701
Principal investigator 1 Eisai Inc. $2,988.90 11/17/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559032
Principal investigator 1 Janssen Research & Development, LLC $8,766.00 11/13/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175398558
Principal investigator 1 Janssen Research & Development, LLC $779.00 11/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398630
Principal investigator 1 Novo Nordisk AS $950.00 10/29/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213744290
Principal investigator 1 Eisai Inc. $1,000.00 10/21/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559030
Principal investigator 1 Eisai Inc. $2,988.90 10/20/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559026
Principal investigator 1 Janssen Research & Development, LLC $2,640.00 09/29/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398597
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,370.46 09/24/2025 Non-covered Recipient Entity
Hattiesburg Clinic Neurology
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235997003
Principal investigator 1 Eisai Inc. $28,927.80 09/15/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559020
Principal investigator 1 Janssen Research & Development, LLC $871.00 09/05/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398581
Principal investigator 1 Novo Nordisk AS $3,005.56 08/22/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213726540
Principal investigator 1 Eisai Inc. $3,634.20 08/11/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559018
Principal investigator 1 Janssen Research & Development, LLC $871.00 08/11/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398671
Principal investigator 1 Eisai Inc. $2,988.90 07/21/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559022
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,580.27 07/14/2025 Non-covered Recipient Entity
Hattiesburg Clinic Neurology
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235997001
Principal investigator 1 Novo Nordisk AS $2,500.00 07/10/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213795178
Principal investigator 1 Eisai Inc. $5,934.60 07/07/2025 Non-covered Recipient Entity
Hattiesburg Clinic-Laboratory
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559024
Principal investigator 1 Janssen Research & Development, LLC $618.00 07/07/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398610
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,797.88 06/25/2025 Non-covered Recipient Entity
Hattiesburg Clinic Family Practice
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235997013
Principal investigator 1 Janssen Research & Development, LLC $4,935.00 06/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175398695
Principal investigator 1 Janssen Research & Development, LLC $6,060.00 06/06/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398574
Principal investigator 1 Biogen, Inc. $858.00 05/21/2025 Non-covered Recipient Entity
Hattiesburg Clinic
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1236947410
Principal investigator 1 Janssen Research & Development, LLC $871.00 05/12/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398636
Principal investigator 1 Janssen Research & Development, LLC $44,649.00 05/08/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175398688
Principal investigator 1 Novo Nordisk AS $6.26 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213818669
Principal investigator 1 Novo Nordisk AS $950.00 04/21/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213731761
Principal investigator 1 Janssen Research & Development, LLC $6,383.00 04/17/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398570
Principal investigator 1 Eli Lilly and Company $42,364.00 04/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187883518
Principal investigator 1 Eli Lilly and Company $631.41 03/26/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187882890
Principal investigator 1 Eli Lilly and Company $4.26 03/26/2025 Non-covered Recipient Entity
SOUTHERN ENDOCRINOLOGY ASSOCIATES PA
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187889848
Recipient Eli Lilly and Company $3,004.87 02/25/2025 Covered Recipient Physician A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187872697
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $1,816.75 02/19/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335529
Principal investigator 1 Janssen Research & Development, LLC $2,386.00 02/10/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175398683
Principal investigator 1 Novo Nordisk AS $2,161.25 01/31/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
NN6535-4725 No dispute reported 06/30/2026 1213839436
Principal investigator 1 Biogen, Inc. $3,250.00 01/28/2025 Non-covered Recipient Entity
Hattiesburg Clinic
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1236948096